Genomics of Probiotics and Prebiotics
Probiotic microscopic organisms from the Lactobacillus and Bifidobacterium species have a place with the Firmicutes and the Actinobacteria phylum, individually. Lactobacilli are individuals of the lactic acid microscopic organisms (LAB) gathering, an extensively characterized group of microorganisms that age different hexoses into basically lactic acid. Lactobacilli are normally low G + C gram-positive species which are phylogenetically with more than 100 species recorded to date. Bifidobacteria are hetero-fermentative, high G + C content microscopic organisms with around 30 types of bifidobacteria depicted to date. Lactobacilli and bifidobacteria are both autochthonous (normally happening) and allochthonous (transient) inhabitants of the gastrointestinal tract (GIT) when conveyed as probiotic societies. Lactobacilli and bifidobacteria are utilized broadly as probiotics; live smaller scale living microorganisms which, when regulated in sufficient amount to give a medical advantage on the host. Lactobacillus species have for some time been related with the creation of aged nourishments, counting dairy items, vegetables, meat, and sourdough bread. Their referred quick fermentation additionally adds to flavour, surface, and food. The expansion of bifidobacteria to nourishments has been later were intentionally included in light of their announced medical advantages and probiotic properties. In spite of the low predominance of lactobacilli in the GI miniaturized scale biology contrasted with the colonic related bifidobacteria, they speak to a noteworthy part of the microbiota dwelling in the small digestive system. Subsequently, certain strains of Lactobacillus, especially those of human root, have been abused as probiotics. Utilization of probiotics is focused towards carriage of these strains into the intestinal tract; consequently these microbes show properties, for example, bile and acid protection.
In addition, Bifidobacterium and a few lactobacilli have the capacities to age oligosaccharides which are not processed by people and thus can present a development advantage for these gainful microbes in the GIT.
Related Conference of Genomics of Probiotics and Prebiotics
October 22-23, 2025
5th International Conference on Tuberculosis, Lung Health and Respiratory Diseases
Paris, France
November 24-25, 2025
17th International Conference on Chronic Obstructive Pulmonary Disease
Barcelona, Spain
April 27-28, 2026
14th International Conference on COPD Clinical Trials & Lung Care Advances
Paris, Aland Islands
June 29-30, 2026
16th International Conference on Pulmonary & Respiratory Medicine
Aix-en-Provence, France
Genomics of Probiotics and Prebiotics Conference Speakers
Recommended Sessions
- Prebiotic Foods
- Applications of probiotics in Aquaculture
- Applications of Probiotics in Health and Diseases
- Biological effects of probiotics
- Common Therapies of Probiotics
- Genomics of Probiotics and Prebiotics
- Health Effects and Applications of Prebiotics
- Mechanisms of Probiotics
- Microbiome and Probiotics
- Prebiotics
- Probiotic Industrial Products
- Probiotic Nutrition
- Probiotics
- Probiotics for Animal Health
- Regulatory perspectives of Probiotics and Prebiotics
- Strains of Probiotics
- Synbiotic
- The Future of Prebiotics and Probiotics
Related Journals
Are you interested in
- Advances in Tuberculosis Diagnosis, Treatment, and Prevention - Tuberculosis-2025 (France)
- Asthma - Pulmonary Meet 2025 (France)
- Asthma and COPD - COPD_2025 (Spain)
- Chronic Bronchitis - Pulmonary Meet 2025 (France)
- Chronic Obstructive Pulmonary Disease - COPD_2025 (Spain)
- Co-Morbidities of COPD - COPD_2025 (Spain)
- Community-based Approaches to TB and Lung Health Awareness - Tuberculosis-2025 (France)
- COPD - Pulmonary Meet 2025 (France)
- COPD and Cardiovascular Diseases - COPD_2025 (Spain)
- COPD Complications - COPD_2025 (Spain)
- COPD Exacerbations - COPD_2025 (Spain)
- COPD Pathogenesis - COPD_2025 (Spain)
- COPD Therapeutics - COPD_2025 (Spain)
- COPD: Sign and Symptoms - COPD_2025 (Spain)
- Cystic Fibrosis - Pulmonary Meet 2025 (France)
- Depression and anxiety in COPD - COPD_2025 (Spain)
- Digital Health Technologies for Respiratory Disease Management - Tuberculosis-2025 (France)
- Drug Discovery of COPD - COPD_2025 (Spain)
- Early Diagnosis and Biomarkers in Respiratory Diseases - Tuberculosis-2025 (France)
- Emerging Respiratory Threats and Pandemic Preparedness - Tuberculosis-2025 (France)
- Emphysema - Pulmonary Meet 2025 (France)
- Epidemiology of COPD - COPD_2025 (Spain)
- Genetic risk factor of COPD - COPD_2025 (Spain)
- Genetics and Susceptibility to Tuberculosis and Lung Diseases - Tuberculosis-2025 (France)
- Global Efforts to Eliminate Tuberculosis by 2030 - Tuberculosis-2025 (France)
- Hospital-acquired Infections and Respiratory Care - Tuberculosis-2025 (France)
- Impact of Smoking and Environmental Factors on Lung Health - Tuberculosis-2025 (France)
- Infectious Respiratory Diseases - Pulmonary Meet 2025 (France)
- Interstitial lung disease - Pulmonary Meet 2025 (France)
- Latent Tuberculosis: Diagnosis, Treatment, and Control - Tuberculosis-2025 (France)
- Lung cancer - COPD_2025 (Spain)
- Lung Cancer - Pulmonary Meet 2025 (France)
- Lung Health: Emerging Trends and Challenges - Tuberculosis-2025 (France)
- Lung problems - Pulmonary Meet 2025 (France)
- Lung transplantation - Pulmonary Meet 2025 (France)
- Multidrug-Resistant Tuberculosis (MDR-TB) and Novel Therapies - Tuberculosis-2025 (France)
- Neonatal and Maternal Respiratory Health - Tuberculosis-2025 (France)
- Novel Therapies and Drug Development for Tuberculosis - Tuberculosis-2025 (France)
- Pathophysiology of COPD - COPD_2025 (Spain)
- Pediatric Pulmonary, Critical care and Sleep - COPD_2025 (Spain)
- Pediatric Tuberculosis and Respiratory Health - Tuberculosis-2025 (France)
- Pleural Diseases - Pulmonary Meet 2025 (France)
- Prevention and Control of Respiratory disease - Pulmonary Meet 2025 (France)
- Pulmonary diseases-treatment and therapies - COPD_2025 (Spain)
- Pulmonary Hypertension - Pulmonary Meet 2025 (France)
- Pulmonary Hypertension - COPD_2025 (Spain)
- Pulmonary Rehabilitation - Pulmonary Meet 2025 (France)
- Pulmonary Rehabilitation and Holistic Care for Respiratory Diseases - Tuberculosis-2025 (France)
- Pulmonary vascular disease - Pulmonary Meet 2025 (France)
- Pulmonology - Pulmonary Meet 2025 (France)
- Respiratory Disorders - Pulmonary Meet 2025 (France)
- Respiratory Infections and Global Public Health Concerns - Tuberculosis-2025 (France)
- Respiratory Infections and Global Public Health Concerns - Tuberculosis-2025 (France)
- Respiratory Tract Infections - Pulmonary Meet 2025 (France)
- Role of Artificial Intelligence in Tuberculosis Diagnosis - Tuberculosis-2025 (France)
- Self-Management and Prevention of COPD - COPD_2025 (Spain)
- Sleep-Related Respiratory Disorders - Pulmonary Meet 2025 (France)
- Tuberculosis - Pulmonary Meet 2025 (France)
- Tuberculosis and HIV Co-infection: Challenges and Treatment - Tuberculosis-2025 (France)
- Tuberculosis Prevention and Global Public Health Strategies - Tuberculosis-2025 (France)
- Types of COPD - COPD_2025 (Spain)